KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) EBIT (2016 - 2025)

Ionis Pharmaceuticals has reported EBIT over the past 17 years, most recently at -$214.5 million for Q4 2025.

  • Quarterly results put EBIT at -$214.5 million for Q4 2025, down 93.52% from a year ago — trailing twelve months through Dec 2025 was -$381.7 million (up 19.66% YoY), and the annual figure for FY2025 was -$381.7 million, up 19.66%.
  • EBIT for Q4 2025 was -$214.5 million at Ionis Pharmaceuticals, down from -$160.2 million in the prior quarter.
  • Over the last five years, EBIT for IONS hit a ceiling of $220.6 million in Q4 2021 and a floor of -$214.5 million in Q4 2025.
  • Median EBIT over the past 5 years was -$91.1 million (2021), compared with a mean of -$82.5 million.
  • Biggest five-year swings in EBIT: soared 1073.36% in 2021 and later crashed 1710.21% in 2024.
  • Ionis Pharmaceuticals' EBIT stood at $220.6 million in 2021, then tumbled by 194.3% to -$208.0 million in 2022, then surged by 97.06% to -$6.1 million in 2023, then crashed by 1710.21% to -$110.8 million in 2024, then plummeted by 93.52% to -$214.5 million in 2025.
  • The last three reported values for EBIT were -$214.5 million (Q4 2025), -$160.2 million (Q3 2025), and $139.8 million (Q2 2025) per Business Quant data.